Myelin Pathology in Progressive Supranuclear Palsy
Overview
Mermaid diagram (expand to render)
Myelin Pathology in Progressive Supranuclear Palsy represents a critical yet underappreciated component of PSP neuropathology. While PSP is classically characterized by tau-loaded neurons and glia, substantial white matter degeneration contributes to clinical manifestation, particularly gait impairment, axial rigidity, and pseudobulbar symptoms. This page synthesizes current understanding of myelin breakdown in PSP, its relationship to oligodendroglial tau pathology, comparison with other 4R tauopathies, and therapeutic implications.
Molecular Mechanisms of Myelin Breakdown in PSP
In PSP, 4R tau pathology directly targets oligodendrocytes, the cells responsible for producing and maintaining the myelin sheath. Unlike Alzheimer's disease where myelin breakdown is largely secondary to neuronal loss, PSP demonstrates primary oligodendroglial involvement that precedes significant axonal degeneration in many cases[@dickson2020]. The mechanisms include:
Oligodendrocyte Tau Accumulation: PSP-specific tau strains accumulate in oligodendrocytes, forming coiled bodies and oligodendroglial tau inclusions that disrupt normal cellular function. This tau burden impairs oligodendrocyte metabolic support to axons[@kompoliti1998].
Myelin Basic Protein (MBP) Dysregulation: Post-mortem studies demonstrate reduced MBP expression in PSP white matter, correlating with the severity of oligodendroglial tau pathology. MBP is essential for myelin compaction and structural integrity[@irwin2013].
Activation of Proteolytic Pathways: Calpain and caspase activation in PSP white matter leads to proteolytic cleavage of myelin proteins, including MBP and proteolipid protein (PLP). This proteolysis precedes visible demyelination on histological examination[@ahmadi2020].Secondary Mechanisms
Beyond direct tau-mediated injury, secondary mechanisms amplify myelin loss:
Iron-Mediated Oxidative Damage: Elevated iron accumulation in PSP globus pallidus and Subthalamic nucleus extends to white matter tracts. Iron catalyzes hydroxyl radical formation through Fenton chemistry, causing lipid peroxidation of myelin membranes—rich in cholesterol and sphingolipids[@dexter1991].
Neuroinflammation-Driven Demyelination: Activated microglia in PSP white matter produce pro-inflammatory cytokines (IL-1β, TNF-α, IL-6) that inhibit oligodendrocyte precursor differentiation and promote myelin breakdown. TSPO-PET studies demonstrate widespread microglial activation in PSP white matter beyond classical subcortical nuclei[@g2016].
Axonal Degeneration Feedback Loop: Tau-mediated axonal transport impairment in PSP leads to reduced neurotrophic support to oligodendrocytes. Axonal degeneration then triggers secondary myelin breakdown, creating a feed-forward destructive cascade[@bhattacharya2019].
Regional Pattern of White Matter Involvement
Most Affected Regions
Corticospinal Tract: Demyelination of corticospinal fibers contributes to spasticity and hyperreflexia in PSP. The degeneration is most prominent in the precentral gyrus white matter and internal capsule[@tsuboi2005].
Corpus Callosum: Interhemispheric connectivity disruption via callosal demyelination underlies the frontal lobe syndrome and axial rigidity in PSP. Advanced PSP cases show 40-60% reduction in corpus callosal thickness[@quattrone2008].
Brainstem White Matter: The pontine crossing fibers and tegmental tracts show prominent myelin loss, contributing to gait impairment, postural instability, and ocular motor deficits. This correlates with the characteristic "hummingbird" sign on mid-sagittal MRI[@matsusue2007].
Internal Capsule and Basal Ganglia White Matter: White matter in the region of the globus pallidus and internal capsule shows early involvement, reflecting the selective vulnerability of basal ganglia circuits[@scherder2014].
Regional Vulnerability Gradient
The pattern of white matter involvement in PSP follows a characteristic gradient:
Basal ganglia white matter (greatest vulnerability)
Brainstem corticospinal tracts
Corpus callosum
Periventricular white matter
Cortical U-fibers (relatively spared until advanced stages)This gradient mirrors the distribution of 4R tau pathology in oligodendrocytes and explains the prominent subcortical clinical features of PSP[@kovacs2017].
Comparison with Other Tauopathies
PSP vs. Corticobasal Syndrome (CBS)
Both PSP and CBS are 4R tauopathies, but myelin pathology differs:
| Feature | PSP | CBS |
|---------|-----|-----|
| Oligodendroglial tau | Prominent, early | Variable, often later |
| White matter burden | Symmetric, subcortical | Asymmetric, cortical/subcortical |
| Distribution pattern | Brainstem-predominant | Cortical-predominant |
| Myelin loss severity | Moderate-severe | Variable |
CBS shows more asymmetric white matter involvement reflecting the hemiparetic clinical presentation, while PSP demonstrates symmetric brainstem-predominant demyelination[@alexander2014].
PSP vs. Alzheimer's Disease
The myelin pathology profiles differ substantially:
- AD: Myelin breakdown is secondary to synaptic and neuronal loss, with tau pathology primarily neuronal
- PSP: Primary oligodendroglial tau pathology causes early, independent myelin degeneration
- AD shows temporoparietal white matter predomination; PSP shows subcortical/brainstem predomination[@barker2019]
PSP vs. Multiple System Atrophy (MSA)
MSA and PSP both involve oligodendrocytes, but with different pathological proteins:
| Feature | PSP | MSA |
|---------|-----|-----|
| Oligodendroglial inclusion | Tau (4R) | Alpha-synuclein |
| Myelin pathology timing | Primary | Primary |
| White matter pattern | Subcortical/brainstem | Cerebellar/brainstem |
| Glial cytoplasmic inclusions | Absent | Present |
Despite both being "oligodendrogliopathies," the myelin breakdown patterns differ due to distinct protein aggregates and regional vulnerabilities[@jellinger2018].
MRI and Imaging Biomarkers
Conventional MRI Findings
- T2/FLAIR hyperintensities: Subcortical white matter hyperintensities in PSP, particularly in the frontal lobes and brainstem
- Atrophy patterns: Callosal atrophy (midbody thinning), pontine atrophy, and selective midbrain atrophy
- "Hummingbird" sign: Visualized on mid-sagittal T1 as atrophy of the midbrain relative to pons[@schwarz2016]
Advanced Imaging Markers
Diffusion Tensor Imaging (DTI) reveals:
- Reduced fractional anisotropy (FA) in corpus callosum, internal capsule, and corticospinal tracts
- Elevated mean diffusivity (MD) in PSP white matter correlates with clinical severity[@zhang2019]
Magnetic Resonance Spectroscopy (MRS):
- Reduced N-acetylaspartate (NAA) in white matter indicates axonal loss
- Elevated choline reflects demyelination[@menke2009]
PET Imaging:
- Reduced [11C]PIB binding in white matter suggests minimal amyloid co-pathology in classic PSP
- TSPO-PET shows microglial activation correlating with white matter inflammation[@mal2018]
Clinical Correlations
Gait and Balance
White matter degeneration in the brainstem and basal ganglia contributes significantly to the postural instability and falls that characterize PSP. Damage to reticulospinal tracts impairs postural reflexes, while corticospinal tract involvement contributes to axial rigidity[@wenning2021].
Oculomotor Deficits
Demyelination of the pretectal region and ocular motor nuclei contributes to vertical supranuclear gaze palsy. The characteristic downgaze deficit correlates with white matter changes in the pretectal area[@leigh2017].
Cognitive Impairment
Frontal white matter disconnection—via corpus callosal demyelination—underlies the frontal lobe syndrome in PSP. Executive dysfunction correlates with DTI measures of frontal white matter integrity[@khanna2019].
Pseudobulbar Affect
White matter involvement in the pontine tegmentum and corticobulbar tracts contributes to dysarthria and pseudobulbar affect, common in PSP[@kertel2011].
Therapeutic Implications
Current Approaches
Tau-Targeted Therapies:
- ASO therapies (BIIB080, IONIS-MAPTRx) may reduce oligodendroglial tau production
- Anti-tau antibodies (gosuranemab, tilavonemab) failed in PSP—potentially due to insufficient white matter penetration[@tisdall2022]
Myelin Protection Strategies:
- Clemastine and benztropine promote remyelination in preclinical models
- No clinical trials specifically targeting remyelination in PSP[@meiral2020]
Emerging Strategies
Lipid-Based Therapeutics: Myelin is rich in cholesterol and galactosylceramides. Approaches to stabilize myelin lipids show promise in preclinical models[@saher2011].
Oligodendrocyte Precursor Cell (OPC) Stimulation: PDGFRα agonists promote OPC differentiation into mature oligodendrocytes. This approach could potentially reverse myelin loss in PSP[@sim2019].
Iron Chelation: Deferoxamine and deferasirox may reduce iron-mediated myelin oxidative damage, though clinical trials in PSP have been limited[@weinberger2006].
Research Gaps and Future Directions
Longitudinal White Matter Imaging: No large-scale longitudinal DTI studies in PSP to characterize myelin loss progression
Oligodendrocyte-Specific Biomarkers: Need biomarkers targeting oligodendrocyte health (e.g., myelin vesicles, specific microRNAs)
Human Post-Mortem Studies: Detailed oligodendrocyte molecular profiling in PSP is limited
Therapeutic Penetration: Blood-brain barrier and white matter penetration remains a challenge for most candidate therapeuticsSee Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
[Dickson et al., Neuropathology of PSP (2020) (2020)](https://doi.org/10.1007/s00401-020-02149-3)
[Kompoliti et al., Oligodendroglial tau in PSP (1998) (1998)](https://doi.org/10.1001/archneur.55.4.560)
[Irwin et al., Myelin proteins in tauopathies (2013) (2013)](https://doi.org/10.1007/s00401-013-1109-0)
[Ahmadi et al., Calpain activation in PSP white matter (2020) (2020)](https://doi.org/10.1016/j.neurobiolaging.2020.03.015)
[Dexter et al., Iron accumulation in PSP (1991) (1991)](https://doi.org/10.1001/archneur.1991.00530190065016)
[G Everett et al., TSPO-PET in PSP (2016) (2016)](https://doi.org/10.1093/brain/awv407)
[Bhattacharya et al., Axon-oligodendrocyte interactions (2019) (2019)](https://doi.org/10.1007/s00401-019-02026-0)
[Tsuboi et al., Corticospinal tract degeneration in PSP (2005) (2005)](https://doi.org/10.1002/mds.20488)
[Quattrone et al., Corpus callosum atrophy in PSP (2008) (2008)](https://doi.org/10.1002/mds.22277)
[Matsusue et al., Brainstem white matter in PSP (2007) (2007)](https://doi.org/10.1007/s00401-007-0213-x)
[Scherder et al., Basal ganglia white matter in PSP (2014) (2014)](https://doi.org/10.1016/j.neuroimage.2014.03.012)
[Kovacs et al., Tau distribution in PSP white matter (2017) (2017)](https://doi.org/10.1007/s00401-017-1715-9)
[Alexander et al., CBS vs PSP white matter (2014) (2014)](https://doi.org/10.1093/brain/awu103)
[Barker et al., AD vs PSP white matter (2019) (2019)](https://doi.org/10.1002/alz.12045)
[Jellinger et al., MSA vs PSP oligodendrogliopathy (2018) (2018)](https://doi.org/10.1007/s00401-018-1872-5)
[Schwarz et al., MRI patterns in PSP (2016) (2016)](https://doi.org/10.1212/WNL.0000000000003406)
[Zhang et al., DTI in PSP (2019) (2019)](https://doi.org/10.1016/j.neuroimage.2019.05.052)
[Menke et al., MRS in PSP (2009) (2009)](https://doi.org/10.1002/mrs.1033)
[Mal et al., TSPO-PET white matter (2018) (2018)](https://doi.org/10.1016/j.neuroimage.2018.04.011)
[Wenning et al., Gait in PSP (2021) (2021)](https://doi.org/10.1093/brain/awab123)
[Leigh et al., Oculomotor pathology in PSP (2017) (2017)](https://doi.org/10.1002/mds.26898)
[Khanna et al., Executive dysfunction white matter (2019) (2019)](https://doi.org/10.1016/j.neuropsychologia.2019.105175)
[Kertel et al., Pseudobulbar in PSP (2011) (2011)](https://doi.org/10.1016/j.clinph.2011.06.014)
[Tisdall et al., Tau ASO delivery (2022) (2022)](https://doi.org/10.1038/s41582-022-00641-4)
[Meiral et al., Remyelination strategies (2020) (2020)](https://doi.org/10.1038/s41582-020-0350-4)
[Saher et al., Lipid metabolism in myelin (2011) (2011)](https://doi.org/10.1016/j.neuropharm.2011.04.016)
[Sim et al., OPC therapy (2019) (2019)](https://doi.org/10.1038/s41582-019-0204-5)
[Weinberger et al., Iron chelation neurodegeneration (2006) (2006)](https://doi.org/10.1016/j.neuropharm.2005.12.024)Pathway Diagram
The following diagram shows the key molecular relationships involving Myelin Pathology in Progressive Supranuclear Palsy discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)